Payment overview · 2025
General Payments
$8,342.95
40 reported records · 10 companies
Healthcare provider profile · identity verified
Nancy Tompkins, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · POPLAR BLUFF, MO · NPI 1922554146
Verified facts
What the public records show
CMS Open Payments records show Nancy Tompkins, FNP-C received $8,342.95 in general payments during 2025 across 40 reported records.
Insulet Corporation accounted for 93.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Korlym, Mounjaro, Ozempic.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Korlym by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $7,800.00 | 93.5% | 14 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $192.16 | 2.3% | 9 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $110.53 | 1.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.03 | 0.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.27 | 0.6% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $36.46 | 0.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.04 | 0.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.86 | 0.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.66 | 0.3% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $21.94 | 0.3% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,800.00 | 14 |
| Food and Beverage | $542.95 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $7,800.00 | 14 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $192.16 | 9 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $110.53 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.03 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.27 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $36.46 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $21.94 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Korlym korlym |
2025 | Korlym | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 170 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
170 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Cefdinir | Cefdinir | 255 | 215 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 67 |
| Gabapentin | Gabapentin | 185 | 49 |
| Lisinopril | Lisinopril | 175 | 59 |
| Ozempic | Semaglutide | 170 | 40 |
| Potassium Chloride | Potassium Chloride | 170 | 42 |
| Losartan Potassium | Losartan Potassium | 162 | 56 |
| Omeprazole | Omeprazole | 157 | 49 |
| Furosemide | Furosemide | 143 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 131 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 39 |
| Montelukast Sodium | Montelukast Sodium | 121 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 29 |
| Trazodone Hcl | Trazodone Hcl | 108 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 30 |
| Glimepiride | Glimepiride | 93 | 26 |
| Buspirone Hcl | Buspirone Hcl | 91 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 85 |
| Mounjaro | Tirzepatide | 90 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 20 |
| Famotidine | Famotidine | 81 | 22 |
| Jardiance | Empagliflozin | 79 | 22 |
| Metformin Hcl | Metformin Hcl | 79 | 28 |
| Metformin Hcl Er | Metformin Hcl | 76 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 25 |
| Eliquis | Apixaban | 70 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 47 |
| Methylprednisolone | Methylprednisolone | 62 | 58 |
| Ezetimibe | Ezetimibe | 59 | 19 |
| Spironolactone | Spironolactone | 59 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 12 |
| Sertraline Hcl | Sertraline Hcl | 52 | 17 |
| Meloxicam | Meloxicam | 51 | 18 |
| Fluconazole | Fluconazole | 48 | 27 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 15 |
| Allopurinol | Allopurinol | 42 | 13 |
| Prednisone | Prednisone | 39 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | 13 |
| Carvedilol | Carvedilol | 35 | 13 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Korlym | Mifepristone | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 19 |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 22 |
| Azithromycin | Azithromycin | 23 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 13 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 13 |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,342.95 · 40 records | Insulet Corporation | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GEMTESA, Korlym, MOUNJARO, OMNIPOD, Ozempic, REZDIFFRA, Rybelsus, TWIIST, t:slim X2 Insulin Pump with Control-IQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Korlym play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Corcept Therapeutics?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error